Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
Life sciences lawyer Lana Gladstein has joined US law firm Nutter McClennen & Fish’s intellectual property practice as partner.   4 March 2015
Americas
AstraZeneca has closed a deal that will see it acquire the rights to Actavis’s branded respiratory drugs business in the US and Canada, it was announced today.   3 March 2015
Big Pharma
The English High Court has ordered the country’s National Health Service to issue guidance to medical professionals so that they prescribe Pfizer’s branded product Lyrica—not the generic version—for neuropathic pain.   3 March 2015
Asia
India-based generic drug maker Natco Pharma has signed a non-exclusive licensing agreement with Gilead Sciences that allows Natco to make and sell generic versions of hepatitis C drugs including Sovaldi, it was announced yesterday.   3 March 2015
Americas
Professional services firm CohnReznick has expanded its technology and life sciences industry practice group to Austin, Texas.   26 February 2015
Americas
Swiss pharmaceutical company Novartis can buy London-based GlaxoSmithKline’s portfolio of cancer drugs after it agreed to meet certain conditions set by the US Federal Trade Commission, the agency has said.   24 February 2015
Americas
Pharmaceutical companies Teva, Momenta, Mylan and Sandoz have asked the US Court of Appeals for the Federal Circuit for an expedited ruling on the validity of Teva’s patent covering its Copaxone drug.   23 February 2015
Americas
Molecular diagnostic company Myriad Genetics has settled the last of its seven BRCA-related patent disputes in the US, this time with genetic testing company GeneDx.   20 February 2015
Big Pharma
The Court of Justice of the European Union has clarified when pharmaceutical patent owners may rely on the Specific Mechanism to prevent parallel imports of their products.   19 February 2015
article
Two years after its launch, the LSIPR monthly is having a re-brand. This issue will be the final one published in a PDF format, as in March we are switching to a ‘digital first’ strategy.   19 February 2015